RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19
Status:
Not yet recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, placebo-controlled clinical trial. This study is to
evaluate the effectiveness and safety of Yinqiaosan-Maxingganshitang in the treatment of the
major symptoms of mild and moderate COVID-19 patients by telemedicine.